康柏西普联合玻璃体切除术治疗增生性糖尿病视网膜病变  

Efficacy of Conbercept combined with vitrectomy in the treatment of proliferative diabetic retinopathy

作　　者：赵学军[1] Zhao Xuejun(Department of Ophthalmology,Central Hospital of Jiaozuo Coal Industry,fiaozuo ,Henan 454150,China)

机构地区：[1]焦作煤业集团中央医院眼科,河南454150

出　　处：《中华眼外伤职业眼病杂志》2019年第1期37-40,共4页Chinese Journal of Ocular Trauma and Occupational Eye Disease

摘　　要：目的探讨玻璃体内注射康柏西普联合玻璃体切除术治疗增生性糖尿病视网膜病变(PDR)的临床效果。方法回顾性分析2014年5月至2017年4月我院眼科PDR玻璃体切除手术治疗204例(215眼)。随机分为两组:对照组,102例(108眼),进行常规玻璃体切除手术;观察组,102例(107眼)在玻璃体切除术前3d行玻璃体内注射康柏西普。术后观察两组治疗效果。结果术前两组间视力、眼压、并发症及黄斑中心区厚度等差异无统计学意义(P>0.05)。术后两组间视力、眼压、并发症及黄斑中心区厚度等差异有统计学意义(P<0.05)。结论PDR玻璃体切除手术前应用康柏西普玻璃体内注射可以减少术中及术后出血、减轻黄斑水肿及提高视功能等。Objective To investigate the clinical efficacy of intravitreal injection of Conbercept combined with vitrectomy in the treatment of proliferative diabetic retinopathy(PDR).Methods The data of 215 eyes 204 cases of PDR from May 2014 to Apr.2017 were analyzed retrospectively.All cases were randomly divided into two groups.The control group,108 eyes of 102 cases,underwent routine vitrectomy;the observation group,107 eyes of 102 cases,received intravitreal injection of Conbercept 3 days before vitrectomy.The efficacy of the two groups was observed after operation.Results The difference in visual acuity,intraocular pressure,complications and central macular thickness were not statistically significant between the two groups before operation (P >0.05).The difference in visual acuity,intraocular pressure, complications and macular central thickness were statistically significant between the two groups after operation (P <0.05 ).Conclusion Intravitreal injection of Conbercept before vitrectomy can reduce hemorrhage and macular edema during and after operation,and can improve visual function.

关 键 词：康柏西普 玻璃体内注射 玻璃体切除术 糖尿病视网膜病变 增生性 黄斑 中心区 厚度 

分 类 号：R779.6[医药卫生—眼科] R587.2[医药卫生—临床医学]